1. Australia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Vita Life Sciences Limited

Vita Life Sciences Limited

AASX:VLS
2.77
AUD
-0.02
(-0.72%)
0.18EPS
13.85P/E
143.18MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
0.64
0.65
0.69
0.69
0.69
0.75
0.78
0.88
1.08
1.26
1.38
1.45
1.67
Basic EPS, GAAP
0.09
0.13
0.08
0.06
0.05
0.04
0.06
0.12
0.16
0.13
0.17
0.16
0.19
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.02
0.04
0.03
0.04
0.04
0.04
0.04
0.04
0.06
0.06
0.06
0.09
0.11
Book Value per Share
0.29
0.38
0.4
0.41
0.44
0.41
0.41
0.46
0.56
0.69
0.77
0.93
1.01
Tangible Book Value per Share
0.29
0.38
0.4
0.41
0.44
0.41
0.41
0.46
0.56
0.69
0.77
0.92
1.01
Basic Weighted Avg Shares
56
56
56
55
55
55
55
53
53
53
54
55
56
Sales/Revenue/Turnover
35
37
39
38
38
41
42
46
57
67
74
80
93
Operating Margin (%)
15.7
18.36
15.74
14.4
12.44
14.77
9.67
16.23
19.28
16.03
16.01
14.66
15.08
Depreciation Expense
- -
- -
- -
- -
- -
- -
1
1
- -
1
1
1
1
Net Income, GAAP
5
7
4
3
3
2
3
6
8
7
9
9
10
Effective Tax Rate (%)
13.96
- -
27.51
40.82
38.92
43.81
30.13
28.14
26.37
31.64
27.09
30.55
27.75
Profit Margin (%)
13.41
19.9
11.38
8.83
7.59
5.93
7.39
13.11
14.52
10.59
12.24
11.05
11.19
Working Capital
15
15
17
15
16
13
14
16
21
26
51
40
42
LT Debt
- -
3
3
2
2
2
2
1
- -
- -
- -
- -
2
Total Equity
16
22
23
23
25
22
23
24
30
37
43
52
56
Return on Invested Capital (%)
33.55
- -
17.18
12.11
10.39
13
11.45
20.62
27.39
21.27
21.4
16.66
17.9
Return on Capital (%)
35.15
- -
18.24
13.44
11.22
9.78
13.29
25.08
29.36
20.18
22.72
18.51
19.22
Return on Common Equity (%)
34.61
38.67
19.83
14.55
11.96
10.35
13.95
25.76
29.9
21.04
22.71
18.35
19.22

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.89%
18.25%
7.42%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
13.51%
13.04%
18.8%
Sales/Revenue/Turnover
9.49%
15.08%
17.31%
Total Cash Common Dividend
13.52%
26.72%
17.6%

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
74
2024
- -
- -
80
2025
- -
- -
93

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.17
2024
- -
- -
0.16
2025
- -
- -
0.19

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.06
2024
- -
- -
0.09
2025
- -
- -
0.11

Company Description

Company Profile APIChatGPT
CEO
Andrew OKeefe
Full Time Employees
400
Sector
Health technology
Industry
Pharmaceuticals: other
Address
1-5 Chalmers Crescent Kirrawee NSW Australia 2020
IPO Date
Aug 23, 2007
Website
vitalifesciences.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Vita Life Sciences Limited is an Australian pharmaceutical and healthcare company engaged in the formulation, packaging, sales and distribution of vitamins, supplements and related health products. The company offers a wide range of premium supplements, vitamins, minerals, herbs and superfoods under its core brands Herbs of Gold, VitaHealth, VitaScience and VitaLife; these products target all age categories and health conditions, including over-the-counter medicines, complementary and alternative medicines, dietary supplements and health foods. It distributes through pharmacies and health food stores across Australia, Malaysia, Singapore, Thailand, Vietnam, China and Indonesia, with over 350 products supported by a team of naturopaths, nutritionists, biotechnologists and pharmacists. Founded in 1947 through its Vita Health origins in Singapore and headquartered in Sydney, Australia, Vita Life Sciences operates as a multinational entity with over 400 employees across seven locations in Australia and Asia. The company sources ingredients globally from sustainable suppliers while manufacturing in key markets to minimize environmental impact; it maintains full ownership of subsidiaries such as Vita Life Sciences (Thailand) Co. Ltd and Vitahealth (Thailand) Co. Ltd. In recent developments, Vita Life Sciences reported strong sales growth in Singapore and Malaysia during the first half of 2025, offsetting softer demand in other markets like Vietnam through new distributor appointments for Herbs of Gold in pharmacy and e-commerce channels; the company also continues its share buy-back program, with updates including purchases as of November 2025, and declared a fully franked dividend of 10.0 cents per share for FY2024, marking the 15th consecutive year. It increased marketing investments to drive brand growth and market penetration amid positive trading conditions, with preliminary financial results for December 2024 showing revenue of $79.5 million and net profit of $8.8 million.